TPCW
DNLI icon

TD Private Client Wealth’s Denali Therapeutics DNLI Stock Holding History

TD Private Client Wealth’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.83K Hold
71
– – ﹤0.01% 1373
2026
Q1 		$1.36K Hold
71
– – ﹤0.01% 1341
2025
Q4 		$1.17K Hold
71
– – ﹤0.01% 1347
2025
Q3 		$1.03K Buy
+71
New +$1.02K ﹤0.01% 1334

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TD Private Client Wealth's DNLI Position: Q2 2026 in Review

TD Private Client Wealth held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 71 shares worth $1.83K. The position accounts for ﹤0.01% of the portfolio, ranked #1373.

TD Private Client Wealth first reported a position in DNLI in Q3 2025 and has held it in 4 quarters since. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • TD Private Client Wealth held 71 shares of Denali Therapeutics worth $1.83K as of Q2 2026.
  • TD Private Client Wealth left its Denali Therapeutics share count unchanged in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1373 holding.
  • TD Private Client Wealth first reported a position in Denali Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.